Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells

Phase 2

Completed

Conditions: Atypical Squamous Cells of Undetermined Significance
Cervical Cancer
High-grade Squamous Intraepithelial Lesion
Low-grade Squamous Intraepithelial Lesion

Interventions: Biological: HspE7
Other: placebo
Other: laboratory biomarker analysis

First Posted Date: 2004-09-08

Last Posted Date: 2013-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 139

Registration Number: NCT00091130

Locations: 🇺🇸
University of California Medical Center At Irvine-Orange Campus, Orange, California, United States

Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery

Not Applicable

Completed

Conditions: Lung Cancer

First Posted Date: 2004-09-08

Last Posted Date: 2013-06-20

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00091039

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: alvocidib

First Posted Date: 2004-09-06

Last Posted Date: 2013-02-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00003039

Locations: 🇺🇸
Clinical Sciences Building, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Cancer Care Specialists of Central Illinois, S.C., Decatur, Illinois, United States

and more 7 locations

Penclomedine in Treating Patients With Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Lymphoma

Interventions: Drug: penclomedine

First Posted Date: 2004-09-03

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00002946

Locations: 🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Biological: recombinant viral vaccine therapy
Biological: sargramostim

First Posted Date: 2004-08-30

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 46

Registration Number: NCT00004029

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma

Phase 2

Completed

Conditions: Ovarian Cancer
Sarcoma

Interventions: Drug: dolastatin 10

First Posted Date: 2004-08-27

Last Posted Date: 2013-02-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT00003778

Locations: 🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States

and more 1 locations

A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: BAY 43-9006

First Posted Date: 2004-08-27

Last Posted Date: 2018-06-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 46

Registration Number: NCT00090545

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Gene Therapy in Treating Patients With Ovarian Cancer

Phase 1

Completed

Conditions: Ovarian Cancer

Interventions: Biological: Ad5CMV-p53 gene
Procedure: laparoscopic surgery

First Posted Date: 2004-08-26

Last Posted Date: 2013-02-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00003588

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Gene Therapy in Treating Patients With Cancer of The Liver

Phase 1

Terminated

Conditions: Liver Cancer

Interventions: Biological: Ad5CMV-p53 gene

First Posted Date: 2004-08-24

Last Posted Date: 2013-02-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00003147

Locations: 🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸
Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States

Vaccine Therapy in Treating Patients With Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

Interventions: Biological: ALVAC-hB7.1
Biological: canarypox-hIL-12 melanoma vaccine

First Posted Date: 2004-08-17

Last Posted Date: 2013-02-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT00003556

Locations: 🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy